KR102652692B1 - A cosmetic compositon comprising antarctic microorganism - Google Patents
A cosmetic compositon comprising antarctic microorganism Download PDFInfo
- Publication number
- KR102652692B1 KR102652692B1 KR1020210084867A KR20210084867A KR102652692B1 KR 102652692 B1 KR102652692 B1 KR 102652692B1 KR 1020210084867 A KR1020210084867 A KR 1020210084867A KR 20210084867 A KR20210084867 A KR 20210084867A KR 102652692 B1 KR102652692 B1 KR 102652692B1
- Authority
- KR
- South Korea
- Prior art keywords
- strain
- skin
- pseudoalteromonas
- liquid
- culture
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 42
- 244000005700 microbiome Species 0.000 title description 24
- 239000000203 mixture Substances 0.000 claims abstract description 52
- 239000000284 extract Substances 0.000 claims abstract description 46
- 239000007788 liquid Substances 0.000 claims abstract description 46
- 241001661345 Moesziomyces antarcticus Species 0.000 claims abstract description 32
- 241000652069 Pseudoalteromonas neustonica Species 0.000 claims abstract description 30
- 238000000855 fermentation Methods 0.000 claims abstract description 25
- 230000004151 fermentation Effects 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000001963 growth medium Substances 0.000 claims description 37
- 239000006071 cream Substances 0.000 claims description 22
- 239000006210 lotion Substances 0.000 claims description 17
- 230000003020 moisturizing effect Effects 0.000 claims description 14
- -1 mask pack Substances 0.000 claims description 11
- 230000008591 skin barrier function Effects 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 230000002087 whitening effect Effects 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000012228 culture supernatant Substances 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000000686 essence Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- 239000003708 ampul Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000005728 strengthening Methods 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 70
- 230000000052 comparative effect Effects 0.000 description 25
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 230000006872 improvement Effects 0.000 description 17
- 239000002609 medium Substances 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 241000519590 Pseudoalteromonas Species 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 230000008099 melanin synthesis Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000004363 Aquaporin 3 Human genes 0.000 description 6
- 108090000991 Aquaporin 3 Proteins 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 229920002444 Exopolysaccharide Polymers 0.000 description 6
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 6
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013028 medium composition Substances 0.000 description 4
- 238000009629 microbiological culture Methods 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 241000519582 Pseudoalteromonas sp. Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108091023242 Internal transcribed spacer Proteins 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102100028314 Filaggrin Human genes 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 슈도지마 안타티카(Pseudozyma antarctica) 균주, 이의 발효액, 파쇄액, 추출액 또는 배양액; 및 슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica) 균주, 이의 발효액, 파쇄액, 추출액 또는 배양액;을 유효성분으로 포함하는 화장료 조성물에 관한 것이다.The present invention relates to Pseudozyma antarctica strain, its fermentation liquid, crushed liquid, extract or culture liquid; and Pseudoalteromonas neustonica strain, its fermentation liquid, crushed liquid, extract or culture liquid; It relates to a cosmetic composition containing as an active ingredient.
Description
본 발명은 남극 유래 미생물 또는 이의 배양액을 함유하는 화장료에 관한 것이다.The present invention relates to cosmetics containing Antarctic-derived microorganisms or their cultures.
피부는 외부환경과 접촉하여 자극에 대한 신체를 보호하는 가장 기초적인 방어기관이며, 외적인 아름다움을 표현하는 중요한 기관이다. The skin is the most basic defense organ that protects the body from irritation in contact with the external environment, and is an important organ that expresses external beauty.
외적인 아름다움이 젊음과 건강을 상징하는 판단의 기준일 뿐 아니라 자신감을 표출하여 업무능력에 영향을 주는 경쟁력으로 자리잡고 있기 때문에, 현대사회에서 피부를 관리하는 경향이 증가하고 있다.Because external beauty is not only a criterion for judgment, symbolizing youth and health, but also a competitive advantage that expresses confidence and affects work ability, the tendency to take care of one's skin is increasing in modern society.
그러나 나이가 들어감에 따라 신진대사를 조절하는 각종 호르몬의 분비가 감소하고, 면역세포의 기능과 세포들의 활성이 저하되어 생체에 필요한 면역 단백질 및 생체 구성 단백질들의 생합성이 감소하고, 외적으로는 오존층 파괴와 같은 환경오염으로 인한 자외선, 자유 라디칼 및 활성산소의 증가로 인하여 발생하는 물리적, 화학적 자극 및 스트레스로 인해 피부의 정상기능이 약화되고 노화가 촉진되며 혈색이 나빠지고 피부가 주름지게 된다.However, as we age, the secretion of various hormones that control metabolism decreases, the function of immune cells and the activity of cells decreases, which reduces the biosynthesis of immune proteins and biocomponent proteins necessary for living organisms, and externally destroys the ozone layer. Due to physical and chemical stimulation and stress caused by an increase in ultraviolet rays, free radicals, and active oxygen caused by environmental pollution, the normal function of the skin is weakened, aging is accelerated, complexion worsens, and the skin becomes wrinkled.
한편, 멜라닌은 자외선으로부터 피부를 보호하는 역할을 하지만 과도하게 생성될 경우 피부에 색소가 침착되어 기미와 주근깨를 형성하며, 심할 경우 피부암의 원인이 되기도 한다. Meanwhile, melanin plays a role in protecting the skin from ultraviolet rays, but when produced excessively, pigment is deposited on the skin, forming spots and freckles, and in severe cases, it can even cause skin cancer.
따라서, 피부의 색소 침착 현상을 방지하기 위해서는 멜라닌 생성과정의 일부분을 저해하여 멜라닌 생성을 감소시켜야 한다. Therefore, in order to prevent skin pigmentation, melanin production must be reduced by inhibiting part of the melanin production process.
멜라닌은 동, 식물과 미생물계에 널리 존재하는 페놀류의 고분자 천연색소로 표피 기저층에 존재하는 멜라닌 세포(melanocyte) 내의 멜라닌소체(melanosome)에서 합성이 된다.Melanin is a phenolic polymer natural pigment that exists widely in animals, plants, and microorganisms, and is synthesized in melanosomes within melanocytes present in the basal layer of the epidermis.
멜라닌은 L-티로신(L-tyrosine)의 연속적인 산화반응으로 합성되는데, L-티로신은 티로시나아제(tyrosinase)에 의해 L-DOPA(3,4-dihydrozyphenylalanine)으로 전환되고, L-DOPA는 페닐아닌-3,4-퀴논으로 산화되며, 중간 대사산물을 거쳐 최종적으로 멜라닌이 된다. Melanin is synthesized through a continuous oxidation reaction of L-tyrosine. L-tyrosine is converted to L-DOPA (3,4-dihydrozyphenylalanine) by tyrosinase, and L-DOPA is converted to phenyl. It is oxidized to anin-3,4-quinone, and finally becomes melanin through intermediate metabolites.
따라서 피부 미백과 관련된 기능성 화장품의 소재를 개발하기 위해서는 그 물질이 티로시나아제의 활성을 저해하는지의 여부가 중요하다.Therefore, in order to develop materials for functional cosmetics related to skin whitening, it is important to determine whether the material inhibits the activity of tyrosinase.
또한, 정상 피부에서 각질형성세포는 분화과정을 통해 각질(keratin) 또는 필라그린(filaggrin)과 같은 피부 장벽 기능을 유지하는데 중요한 구조 단백질을 발현시켜 수분 손실 및 여러 환경적 침해로부터 피부를 보호한다.Additionally, in normal skin, keratinocytes protect the skin from moisture loss and various environmental insults by expressing structural proteins important for maintaining skin barrier function, such as keratin or filaggrin, through the differentiation process.
보습과 피부장벽은 외부환경의 변화와 생활패턴의 변화의 따라 온도의 급격한 변화, 환경오염으로 인한 자극, 각종 스트레스, 무리한 세안 및 연령증가에 의한 자연스러운 노화를 원인으로 달라질 수 있다. Moisturization and skin barrier can change due to changes in the external environment and lifestyle patterns, rapid changes in temperature, irritation due to environmental pollution, various stresses, excessive washing of the face, and natural aging due to increasing age.
이러한 현상을 방지하고 톤이 밝은 피부를 유지하기 위해서, 기존에 알려진 각종 동물, 식물, 미생물 등으로부터 얻은 생리 활성 물질들을 화장품에 부가하여 산화로 인한 피부노화를 방지함으로써 피부를 개선시키고자 노력하고 있으며, 특히 화장품 업계는 여러 화학물질 등에 의한 피부 자극을 줄이기 위해 천연물을 사용한 다수의 제품을 개발하고 있다. In order to prevent this phenomenon and maintain bright skin tone, we are trying to improve the skin by adding bioactive substances obtained from various known animals, plants, and microorganisms to cosmetics to prevent skin aging due to oxidation. , In particular, the cosmetics industry is developing a number of products using natural products to reduce skin irritation caused by various chemicals.
천연 재료는 피부에 부작용이 적을 뿐 아니라, 최근 천연 재료를 이용한 화장품에 대한 소비자들의 호응이 높아짐에 따라 화장품 원료로서 개발가치가 점차 증가하고 있다.Not only do natural ingredients have fewer side effects on the skin, but their development value as cosmetic raw materials is gradually increasing as consumers' response to cosmetics using natural ingredients has recently increased.
현 상황에서 미생물을 이용한 발효물 및 바이오 전환 기술이 화장품 소재 분야에서 적극적으로 활용되고 있으며, 이를 통해 멜라닌 생성을 효과적으로 억제할 뿐만 아니라 즉각적으로 피부 보습에 영향을 주는 미생물 기반 화장품 소재를 찾아내기 위한 노력이 요구되고 있다.In the current situation, fermented products and bio-conversion technology using microorganisms are being actively used in the field of cosmetic materials, and through this, efforts are being made to find microorganism-based cosmetic materials that not only effectively suppress melanin production but also immediately affect skin moisturization. This is being demanded.
본 발명은 전술한 종래 기술의 문제점을 해결하기 위한 것으로, 본 발명의 목적은 생체 안전성과 함께 피부 개선 활성이 우수한 친환경 화장료 원료를 제공하는 것이다.The present invention is intended to solve the problems of the prior art described above, and the purpose of the present invention is to provide an eco-friendly cosmetic raw material with excellent skin improvement activity as well as biosafety.
본 발명의 일 측면에 따르면, 상기 슈도지마 안타티카(Pseudozyma antarctica) 균주, 이의 발효액, 파쇄액, 추출액 또는 배양액; 및 슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica) 균주, 이의 발효액, 파쇄액, 추출액 또는 배양액;을 유효성분으로 포함하는 화장료 조성물이 제공된다.According to one aspect of the present invention, the Pseudozyma antarctica strain, its fermentation broth, lysate, extract or culture broth; and Pseudoalteromonas neustonica strain, its fermentation liquid, crushed liquid, extract or culture liquid; provided is a cosmetic composition containing as an active ingredient.
일 실시예에 있어서, 상기 슈도지마 안타티카(Pseudozyma antarctica) 균주는 슈도지마 안타티카 LAB-10(수탁번호: KCTC 14550BP)일 수 있다.In one embodiment, the Pseudozyma antarctica strain is Pseudozyma antarctica LAB-10 (Accession number: It may be KCTC 14550BP).
일 실시예에 있어서, 슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica) 균주는 슈도알테로모나스 뉴스토니카 LAB-08(수탁번호: KCTC 14549BP)일 수 있다.In one embodiment, the Pseudoalteromonas neustonica strain may be Pseudoalteromonas neustonica LAB-08 (Accession number: KCTC 14549BP).
일 실시예에 있어서, 상기 배양액은 슈도지마 안타티카(Pseudozyma antarctica) 균주 또는 슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica) 균주를 배양하여 수득된 배양액 자체, 또는 이로부터 균주를 제거하여 수득된 배양 상층액, 또는 배양 상층액의 농축물 또는 동결건조물일 수 있다.In one embodiment, the culture medium is the culture medium itself obtained by culturing the Pseudozyma antarctica strain or the Pseudoalteromonas neustonica strain, or the culture supernatant obtained by removing the strain therefrom. , or it may be a concentrate or lyophilized product of the culture supernatant.
일 실시예에 있어서, 상기 화장료 조성물은 피부 보습 또는 피부장벽강화용일 수 있다.In one embodiment, the cosmetic composition may be for moisturizing skin or strengthening the skin barrier.
일 실시예에 있어서, 상기 화장료 조성물은 피부 미백용 또는 피부톤 개선용일 수 있다.In one embodiment, the cosmetic composition may be used for skin whitening or skin tone improvement.
일 실시예에 있어서, 상기 화장료 조성물 유연화장수, 영양화장수, 수분크림, 영양크림, 마사지크림, 영양로션, 에센스, 앰플, 젤, 아이크림, 오일, 파운데이션, 클렌징크림, 클렌징폼, 클렌징워터, 마스크팩, 스프레이 및 파우더로 이루어진 군에서 선택된 하나의 제형으로 이루어질 수 있다.In one embodiment, the cosmetic composition includes softening lotion, nourishing lotion, moisturizing cream, nourishing cream, massage cream, nourishing lotion, essence, ampoule, gel, eye cream, oil, foundation, cleansing cream, cleansing foam, cleansing water, and mask. It may consist of one formulation selected from the group consisting of pack, spray, and powder.
본 발명의 다른 측면에 따르면, 슈도지마 안타티카(Pseudozyma antarctica) 균주, 이의 발효액, 파쇄액, 추출액 또는 배양액; 및 슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica) 균주, 이의 발효액, 파쇄액, 추출액 또는 배양액;을 유효성분으로 포함하는 피부외용제 조성물이 제공된다. According to another aspect of the present invention, Pseudozyma antarctica strain, its fermentation liquid, crushed liquid, extract or culture liquid; and Pseudoalteromonas neustonica strain, its fermentation liquid, crushed liquid, extract or culture medium; provided is an external skin composition containing as an active ingredient.
본 발명에 따르면, 상기 남극 유래의 미생물은 발효 과정에서 피부에 유익한 성분을 다량 생성하여, 멜라닌 생성을 효과적으로 억제하며 피부 보습 효과가 우수하다.According to the present invention, the Antarctic-derived microorganism produces a large amount of ingredients beneficial to the skin during the fermentation process, effectively suppresses melanin production and has an excellent skin moisturizing effect.
본 발명의 효과는 상기한 효과로 한정되는 것은 아니며, 본 발명의 상세한 설명 또는 청구범위에 기재된 발명의 구성으로부터 추론 가능한 모든 효과를 포함하는 것으로 이해되어야 한다.The effects of the present invention are not limited to the effects described above, and should be understood to include all effects that can be inferred from the configuration of the invention described in the detailed description or claims of the present invention.
도 1은 본 발명의 일 실시예에 따른 균주 배양액 및 추출액의 멜라닌 생성 억제 효과를 평가한 결과이다.
도 2 및 3은 본 발명의 일 실시예에 따른 균주 배양액 및 추출액 처리에 따른 AQP3 및 HAS3 발현량을 평가한 결과이다.
도 4는 본 발명의 일 실시예에 따른 균주 배양액 및 추출액 처리에 따른 피부톤 개선 효과를 측정한 결과이다.Figure 1 shows the results of evaluating the melanin production inhibition effect of strain culture and extract according to an embodiment of the present invention.
Figures 2 and 3 show the results of evaluating the expression levels of AQP3 and HAS3 according to treatment of the strain culture and extract according to an embodiment of the present invention.
Figure 4 shows the results of measuring the effect of improving skin tone according to treatment of the strain culture medium and extract according to an embodiment of the present invention.
본 명세서에서 사용되는 용어는 본 발명에서의 기능을 고려하면서 가능한 현재 널리 사용되는 일반적인 용어들을 선택하였으나, 이는 당 분야에 종사하는 기술자의 의도 또는 판례, 새로운 기술의 출현 등에 따라 달라질 수 있다. The terms used in this specification are general terms that are currently widely used as much as possible while considering the function in the present invention, but this may vary depending on the intention or precedent of a person skilled in the art, the emergence of new technology, etc.
또한, 특정한 경우는 출원인이 임의로 선정한 용어도 있으며, 이 경우 해당되는 발명의 설명 부분에서 상세히 그 의미를 기재할 것이다. 따라서 본 발명에서 사용되는 용어는 단순한 용어의 명칭이 아닌, 그 용어가 가지는 의미와 본 발명의 전반에 걸친 내용을 토대로 정의되어야 한다.In addition, in certain cases, there are terms arbitrarily selected by the applicant, and in this case, the meaning will be described in detail in the description of the relevant invention. Therefore, the terms used in the present invention should be defined based on the meaning of the term and the overall content of the present invention, rather than simply the name of the term.
다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다. Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by a person of ordinary skill in the technical field to which the present invention pertains. Terms defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related technology, and unless clearly defined in the present application, should not be interpreted in an ideal or excessively formal sense. No.
수치 범위는 상기 범위에 정의된 수치를 포함한다. 본 명세서에 걸쳐 주어진 모든 최대의 수치 제한은 낮은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 낮은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 최소의 수치 제한은 더 높은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 높은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 수치 제한은 더 좁은 수치 제한이 명확히 쓰여져 있는 것처럼, 더 넓은 수치 범위 내의 더 좋은 모든 수치 범위를 포함할 것이다.The numerical range includes the values defined in the range above. Every maximum numerical limit given throughout this specification includes all lower numerical limits as if the lower numerical limit were explicitly written out. Every minimum numerical limit given throughout this specification includes every higher numerical limit as if such higher numerical limit was clearly written. All numerical limits given throughout this specification will include all better numerical ranges within the broader numerical range, as if the narrower numerical limits were clearly written.
이하, 본 발명의 실시예를 상세히 기술하나, 하기 실시예에 의해 본 발명이 한정되지 아니함은 자명하다.Hereinafter, examples of the present invention will be described in detail, but it is obvious that the present invention is not limited to the following examples.
본 발명의 일 측면은 슈도지마 안타티카(Pseudozyma antarctica) 균주, 이의 발효액, 파쇄액, 추출액 또는 배양액; 및 슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica) 균주, 이의 발효액, 파쇄액, 추출액 또는 배양액;을 유효성분으로 포함하는 화장료 조성물을 제공한다.One aspect of the present invention is Pseudozyma antarctica strain, its fermentation liquid, crushed liquid, extract or culture liquid; and Pseudoalteromonas neustonica strain, its fermentation liquid, crushed liquid, extract or culture liquid; provided as an active ingredient.
본 발명자들은 슈도지마 안타티카 균주 및 슈도알테로모나스 뉴스토니카 균주의 배양액 및 추출액의 우수한 피부 개선 효과를 확인하였으며, 이를 통해 피부 미백, 피부 보습을 위한 화장품 원료로서 사용할 수 있음을 규명하였다.The present inventors confirmed the excellent skin improvement effect of the culture medium and extract of the Pseudojima antatica strain and the Pseudoalteromonas newtonica strain, and through this, they confirmed that it can be used as a cosmetic raw material for skin whitening and skin moisturizing.
상기 "슈도지마 안타티카(Pseudozyma antarctica)"는 남극에서 분리 및 동정된 미생물로 유화물질을 생성할 수 있으며, 배양 및 발효 과정에서 미백 활성을 가지는 점성 다당체(EPS)를 다량 생성하여, 피부 미백 및 피부톤 개선을 위한 용도로서 사용할 수 있다.The " Pseudozyma antarctica " is a microorganism isolated and identified in Antarctica that can produce emulsified substances, and produces a large amount of viscous polysaccharide (EPS) with whitening activity during the culture and fermentation process, thereby improving skin whitening and skin tone. It can be used for improvement purposes.
상기 “슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica)”균주는 남극 로스해(Ross Sea) 해수면 미세층에서 분리 및 동정된 미생물로, 배양 및 발효 과정에서 피부 보습 활성을 가지는 GG(GlycerylGlucoside)를 다량 생성하여, 피부 보습 및 피부장벽강화를 위한 용도로서 사용할 수 있다.The “ Pseudoalteromonas neustonica ” strain is a microorganism isolated and identified from the microlayer of the sea surface of the Ross Sea in Antarctica, and produces a large amount of GG (GlycerylGlucoside), which has skin moisturizing activity, during the culture and fermentation process. It can be used to moisturize the skin and strengthen the skin barrier.
특히, 본 발명자들은 상기 균주의 발효액, 추출액, 배양액은 동시에 작용할 때 상호 시너지 활성을 통해 더욱 우수한 기능성을 나타낼 수 있음을 확인하였다.In particular, the present inventors confirmed that the fermentation broth, extract, and culture broth of the above strain can exhibit superior functionality through mutual synergistic activity when acting simultaneously.
상기 슈도지마 안타티카(Pseudozyma antarctica) 균주는 슈도지마 안타티카 LAB-10(수탁번호: KCTC 14550BP)일 수 있고, 상기 슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica) 균주는 슈도알테로모나스 뉴스토니카 LAB-08(수탁번호: KCTC 14549BP)일 수 있다.The Pseudozyma antarctica strain may be Pseudozyma antarctica LAB-10 (accession number: KCTC 14550BP), and the Pseudoalteromonas neustonica strain may be Pseudoalteromonas neustonica LAB- It may be 08 (Accession number: KCTC 14549BP).
본 발명자들은 국내의 한 지역(지리산 얼음골)에서 수득한 미생물을 동정한 결과 남극에서 유래한 슈도지마 안타티카 균주 및 슈도알테로모나스 뉴스토니카 균주임을 확인하였으며, 종래의 남극 미생물과 비교하여 더욱 우수한 피부 개선 활성을 나타낼 수 있음을 확인하였다.The present inventors identified microorganisms obtained from an area in Korea (Eoreumgol, Jirisan Mountain) and confirmed that they were Pseudojima antatica and Pseudoalteromonas newtonica strains originating from Antarctica, and had better skin properties compared to conventional Antarctic microorganisms. It was confirmed that improvement activity can be shown.
상기 배양액은 슈도지마 안타티카(Pseudozyma antarctica) 균주 또는 슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica) 균주를 배양하여 수득된 배양액 자체, 또는 이로부터 균주를 제거하여 수득된 배양 상층액, 또는 배양 상층액의 농축물 또는 동결건조물일 수 있다.The culture medium is the culture medium itself obtained by culturing the Pseudozyma antarctica strain or the Pseudoalteromonas neustonica strain, or the culture supernatant obtained by removing the strain therefrom, or the culture supernatant. It may be a concentrate or lyophilisate.
상기 배양액은 슈도지마 안타티카 균주 또는 슈도알테로모나스 뉴스토니카 균주를 글루코오스, 프룩토오스, 만노오스, 갈락토오스, 자일로스, 리보오스, 말토오스, 수크로오스, 덱스트린, 글리세린, 및 이눌린으로 이루어진 군으로부터 선택된 1종 이상의 탄소원; 및 질산칼륨, 질산암모늄, 황산암모늄, 옥살산암모늄, 및 인산이암모늄 이눌린으로 이루어진 군으로부터 선택된 1종 이상의 질소원을 포함하는 배지에 상기 균주를 배양시켜 수득한 것일 수 있다.The culture medium is a Pseudomonas antatica strain or a Pseudoalteromonas newtonica strain with one or more selected from the group consisting of glucose, fructose, mannose, galactose, xylose, ribose, maltose, sucrose, dextrin, glycerin, and inulin. carbon source; and one or more nitrogen sources selected from the group consisting of potassium nitrate, ammonium nitrate, ammonium sulfate, ammonium oxalate, and diammonium inulin phosphate.
상기 배양 배지에서 사용되는 탄소원 또는 질소원은 예컨대, 약 0.1 내지 30 w/v%, 1 내지 25 w/v%, 1 내지 20 w/v%, 1 내지 10 w/v%, 1 내지 5w/v%, 또는 1 내지 1.5 w/v%로 포함될 수 있다. The carbon source or nitrogen source used in the culture medium is, for example, about 0.1 to 30 w/v%, 1 to 25 w/v%, 1 to 20 w/v%, 1 to 10 w/v%, 1 to 5 w/v. %, or 1 to 1.5 w/v%.
상기 배양 배지는 균주의 배양 배지에서 통상적으로 사용되는 염을 포함할 수 있고, 상기 염은 예컨대 질산칼륨, 황산칼륨, 탄산마그네슘, 황산마그네슘, 및 질산마그네슘으로 이루어진 군으로부터 선택된 1종 이상의 염을 포함할 수 있으며, 상기 염은 예컨대, 약 0.01 내지 10 w/v%, 0.1 내지 7 w/v%, 또는 0.5 내지 5 w/v%로 포함될 수 있다.The culture medium may contain a salt commonly used in the culture medium of the strain, and the salt includes, for example, one or more salts selected from the group consisting of potassium nitrate, potassium sulfate, magnesium carbonate, magnesium sulfate, and magnesium nitrate. For example, the salt may be included at about 0.01 to 10 w/v%, 0.1 to 7 w/v%, or 0.5 to 5 w/v%.
상기 배양 배지는 약 0.01 내지 10w/v%, 0.05 내지 5 w/v%, 또는 0.1 내지 2w/v%의 효모 자가 용해물을 포함할 수 있으며, 상기 배양 배지는 약 2.0 내지 7.0의 pH일 수 있으나 이에 제한되지 않는다.The culture medium may include about 0.01 to 10 w/v%, 0.05 to 5 w/v%, or 0.1 to 2 w/v% yeast autolysate, and the culture medium may have a pH of about 2.0 to 7.0. However, it is not limited to this.
상기 배양액은 상기 슈도지마 안타티카 균주 또는 슈도알테로모나스 뉴스토니카 균주를 예컨대, 약 20 내지 42℃, 약 25 내지 35 ℃, 또는 약 27 내지 30 ℃ 의 온도 조건 하에 예컨대 약 24내지 144시간, 48 내지 120시간, 또는 15 내지 35시간 동안 배양하여 수득된 것일 수 있다.The culture medium is grown by cultivating the Pseudojima antatica strain or Pseudoalteromonas newtonica strain under temperature conditions of, for example, about 20 to 42°C, about 25 to 35°C, or about 27 to 30°C for, for example, about 24 to 144 hours, 48 hours. It may be obtained by culturing for from 120 hours to 120 hours, or from 15 to 35 hours.
상기 균주의 배양 조건은 배지에서 상기 균주를 첨가하여 발효시키는 단계를 포함할 수 있으며, 발효시키는 단계는 통상적으로 사용하는 발효 방법을 사용할 수 있으며, 예컨대 상기 방법은 유가식(fed batch) 발효를 사용할 수 있다.The culture conditions of the strain may include the step of adding the strain to the medium and fermenting it, and the fermentation step may use a commonly used fermentation method, for example, the method may use fed batch fermentation. You can.
상기 추출액은 분리된 상기 슈도지마 안타티카 균주 또는 슈도알테로모나스 뉴스토니카 균주의 배양액을 여러 유기용매로 추출하여 수득한 것일 수 있다.The extract may be obtained by extracting the culture medium of the isolated Pseudojima antatica strain or Pseudoalteromonas newtonica strain with various organic solvents.
상기 파쇄액은 상기 슈도지마 안타티카 균주 또는 슈도알테로모나스 뉴스토니카 균주의 배양액으로부터 균주를 분리한 후 기계적인 방법(mechanical methods) 또는 비기계적인 방법(nonmechanical methods)을 통해 세포벽 또는 세포막을 파쇄시키고 세포 내 생성물(intracellular products)을 방출시켜 수득한 것일 수 있다.The lysate is produced by separating the strain from the culture medium of the Pseudojima antatica strain or Pseudoalteromonas newtonica strain and then crushing the cell wall or cell membrane through mechanical methods or nonmechanical methods. It may be obtained by releasing intracellular products.
상기 발효액은 상기 슈도지마 안타티카 균주 또는 슈도알테로모나스 뉴스토니카 균주를 배양하고 발효 과정이 완료된 액체 배지 또는 이로부터 지용성 성분을 추출하여 수득한 것일 수 있다.The fermented broth may be obtained by culturing the Pseudojima antatica strain or the Pseudoalteromonas newtonica strain and extracting fat-soluble components from a liquid medium or a liquid medium in which the fermentation process is completed.
상기 화장료 조성물은 상기 슈도지마 안타티카 균주 및 슈도알테로모나스 뉴스토니카 균주를 조성물 총 중량에 대하여 예컨대 1 내지 99.99 중량%, 예컨대, 1.5 내지 99.99 중량%, 2 내지 99.99 중량% 포함할 수 있다.The cosmetic composition may contain, for example, 1 to 99.99% by weight, for example, 1.5 to 99.99% by weight, or 2 to 99.99% by weight of the Pseudojima antatica strain and Pseudoalteromonas newtonica strain, based on the total weight of the composition.
상기 슈도지마 안타티카 균주 및 슈도알테로모나스 뉴스토니카 균주, 이의 발효액, 파쇄액, 추출액 또는 배양액은 멜라닌 생성량을 유의하게 감소시키고, 동시에 피부 보습 활성을 나타낼 수 있다는 측면에서 화장료 조성물 총 중량에 대하여 2%(w/w) 이상 포함될 수 있다.In that the Pseudojima antatica strain and Pseudoalteromonas newtonica strain, their fermentation broth, crushed liquid, extract liquid or culture medium can significantly reduce the amount of melanin produced and at the same time exhibit skin moisturizing activity, 2 relative to the total weight of the cosmetic composition. It may contain more than %(w/w).
상기 화장료 조성물은 피부 보습 또는 피부 장벽 강화용일 수 있다.The cosmetic composition may be used to moisturize the skin or strengthen the skin barrier.
상기 "피부 보습"은 피부의 수분 손실(수분 증발) 등을 적절히 조절하여 피부조직의 항상성을 유지하는 모든 행위를 의미한다. 상기 피부 보습 효과는 각질 개선효과, 피부자극 감소효과 등 다양한 측면의 추가적인 피부 개선 효과를 수반할 수 있다.The term “skin moisturizing” refers to all actions that maintain homeostasis of skin tissue by appropriately controlling moisture loss (water evaporation) of the skin. The skin moisturizing effect may be accompanied by additional skin improvement effects in various aspects such as keratin improvement effect and skin irritation reduction effect.
상기 “피부장벽”이란 피부 구조는 외부에 드러나 있는 표피와 안쪽의 진피로 나뉘는데 표피에서도 가장 바깥쪽에 위치한 각질층에 해당하는 부분이다. 상기 피부장벽의 역할은 외부 유해 요소가 피부에 침입하지 못하도록 방어하면서, 내부 수분이 빠져나가지 않도록 보호하는 것이다.The skin structure referred to as the “skin barrier” is divided into the outer epidermis and the inner dermis, which corresponds to the outermost stratum corneum of the epidermis. The role of the skin barrier is to prevent external harmful elements from invading the skin and to prevent internal moisture from escaping.
상기 “피부장벽강화”란 피부 장벽이 약해지면 외부 자극에 취약해지고 수분을 쉽게 잃어 피부가 건조, 민감해질 가능성이 높아지는 바, 이를 예방, 방지 또는 개선하는 것을 말한다.The term “skin barrier strengthening” refers to the prevention, prevention, or improvement of the fact that when the skin barrier is weakened, it becomes vulnerable to external stimuli and loses moisture easily, increasing the likelihood that the skin will become dry and sensitive.
상기 화장료 조성물은 피부 미백용 또는 피부톤 개선용일 수 있다.The cosmetic composition may be used for skin whitening or skin tone improvement.
상기 "피부 미백"은 피부색에 영향을 미치는 멜라닌, 산화-환원 헤모글로빈, 카로틴, 멜라노이드 등 다양한 생체 분자의 생성을 억제함으로써 잡티, 주근깨, 기미 등의 피부 색소 침착 현상을 완화시키고, 피부 누런기, 붉은기를 완화시켜 피부 밝기 및 균일도를 향상시키는 효과를 의미한다.The “skin whitening” suppresses the production of various biomolecules such as melanin, redox hemoglobin, carotene, and melanoids that affect skin color, thereby alleviating skin pigmentation such as blemishes, freckles, and freckles, and reducing skin yellowness. This refers to the effect of alleviating redness and improving skin brightness and uniformity.
상기기 “피부톤 개선”은 피부의 색을 밝게하고 피부 결을 부드럽게 해주는 것을 의미한다. 상기 피부톤은 멜라닌 색소에 영향을 받기 때문에 상기 피부톤 개선 효과는 피부 미백 효과가 동반될 수 있다. The term “improvement of skin tone” refers to brightening skin color and smoothing skin texture. Since the skin tone is influenced by melanin pigment, the skin tone improvement effect may be accompanied by a skin whitening effect.
상기 화장료 조성물 유연화장수, 영양화장수, 수분크림, 영양크림, 마사지크림, 영양로션, 에센스, 앰플, 젤, 아이크림, 오일, 파운데이션, 클렌징크림, 클렌징폼, 클렌징워터, 마스크팩, 스프레이 및 파우더로 이루어진 군에서 선택된 하나의 제형으로 이루어질 수 있으나 이에 제한되는 것은 아니다.The cosmetic composition includes softening lotion, nourishing lotion, moisturizing cream, nourishing cream, massage cream, nourishing lotion, essence, ampoule, gel, eye cream, oil, foundation, cleansing cream, cleansing foam, cleansing water, mask pack, spray and powder. It may consist of one formulation selected from the group, but is not limited thereto.
본 발명의 다른 측면에 따르면, 슈도지마 안타티카(Pseudozyma antarctica) 균주, 이의 발효액, 파쇄액, 추출액 또는 배양액; 및 슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica) 균주, 이의 발효액, 파쇄액, 추출액 또는 배양액;을 유효성분으로 포함하는 피부외용제 조성물이 제공된다. According to another aspect of the present invention, Pseudozyma antarctica strain, its fermentation liquid, crushed liquid, extract or culture liquid; and Pseudoalteromonas neustonica strain, its fermentation liquid, crushed liquid, extract or culture medium; provided is an external skin composition containing as an active ingredient.
상기 피부 외용제 조성물은 크림, 젤, 패치, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 및 카타플라스마제로 이루어진 군에서 선택된 하나 이상으로 제형화될 수 있으나, 이에 제한되는 것은 아니다.The composition for external application to the skin may be formulated with one or more selected from the group consisting of creams, gels, patches, sprays, ointments, warning agents, lotions, liniment agents, pasta agents, and cataplasma agents, but is not limited thereto.
상기 화장료 조성물은 통상의 방법에 의해 제형화될 수 있다. 상기 화장료 조성물의 제형화에 있어서, 예컨대, International cosmetic ingredient dictionary, 6th ed(The cosmetic, Toiletry and Fragrance Association, Inc., Washington, 1995)에 개시되어 있는 내용을 참조할 수 있고, 상기 피부 외용제의 제형화에 있어서 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 내용을 참조할 수 있다.The cosmetic composition can be formulated by conventional methods. In formulating the cosmetic composition, for example, the content disclosed in the International cosmetic ingredient dictionary, 6th ed (The cosmetic, Toiletry and Fragrance Association, Inc., Washington, 1995) may be referred to, and the formulation of the skin external preparation In this regard, reference may be made to the content disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA.
구체적으로, 상기 화장료 조성물은 일반적인 유화 제형 및 가용화 제형으로 제조할 수 있다. 예컨대, 유연 화장수 또는 영양 화장수 등의 화장수; 훼이셜 로션, 바디로션 등의 유액; 영양 크림, 수분 크림, 아이 크림 등의 크림; 에센스; 화장연고; 스프레이; 젤; 팩; 선 스크린; 메이크업 베이스; 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션; 파우더; 클렌징 크림, 클렌징 로션, 클렌징 오일 등의 메이크업 제거제; 또는 클렌징 폼, 비누, 바디워시 등의 세정제로 제형화될 수 있으나 이에 한정되는 것은 아니다. Specifically, the cosmetic composition can be prepared in a general emulsified formulation and solubilized formulation. For example, lotion such as softening lotion or nourishing lotion; Emulsions such as facial lotion and body lotion; Creams such as nutritional cream, moisture cream, eye cream, etc.; essence; cosmetic ointment; spray; gel; pack; sunscreen; makeup base; Foundation, such as liquid type, solid type, or spray type; powder; Make-up removers such as cleansing creams, cleansing lotions, and cleansing oils; Alternatively, it may be formulated as a cleansing agent such as cleansing foam, soap, or body wash, but is not limited to this.
상기 화장료 조성물 및 피부 외용제 조성물은 각각의 제형에 있어서 상기 필수성분 외에 제형의 종류 또는 사용 목적 등에 따라 본 발명에 따른 목적을 저해하지 않는 범위 내에서 다른 성분들이 적절히 배합될 수 있다.In addition to the above essential ingredients, other ingredients may be appropriately mixed in the cosmetic composition and skin external composition in each formulation, depending on the type of formulation or purpose of use, within the range that does not impair the purpose of the present invention.
상기 화장료 조성물 및 피부 외용제 조성물은 통상적으로 허용 가능한 담체를 포함할 수 있으며, 예컨대 유분, 물, 계면활성제, 보습제, 저급 알코올, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 한정되는 것은 아니다.The cosmetic composition and external skin preparation composition may contain commonly acceptable carriers, such as oil, water, surfactant, moisturizer, lower alcohol, thickener, chelating agent, colorant, preservative, fragrance, etc., may be appropriately mixed. It is not limited to this.
상기 허용 가능한 담체는 제형에 따라 달리할 수 있다. 예컨대, 연고, 페이스트, 크림 또는 젤로 제형화될 때 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 혼합물이 사용될 수 있다.The acceptable carrier may vary depending on the formulation. For example, when formulated into ointments, pastes, creams or gels, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or these are used as carrier ingredients. Mixtures may be used.
상기 화장료 조성물 및 피부 외용제 조성물은 파우더 또는 스프레이로 제형화될 때, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 사용될 수 있고, 스프레이의 경우 클로로플루오로히드로카본, 프로판, 부탄 또는 디메틸 에테르와 같은 추진제를 더 포함할 수 있다.When the cosmetic compositions and external skin compositions are formulated as powders or sprays, lactose, talc, silica, aluminum hydroxide, calcium silcate, polyamide powder, or mixtures thereof may be used as carrier ingredients, and in the case of sprays, It may further include propellants such as chlorofluorohydrocarbon, propane, butane or dimethyl ether.
상기 화장료 조성물 및 피부 외용제 조성물은 용액 또는 유탁액으로 제형화될 때, 담체 성분으로서 용매, 용해화제, 또는 유탁화제가 사용될 수 있고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-브틸글리콜 오일이 사용될 수 있고, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브 오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 사용될 수 있다. When the cosmetic compositions and compositions for topical skin application are formulated as a solution or emulsion, a solvent, solubilizing agent, or emulsifying agent may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, and benzyl benzoate. , propylene glycol, 1,3-butyl glycol oil can be used, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan. can be used
상기 화장료 조성물 및 피부 외용제 조성물은 현탁액으로 제형화될 때, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리 옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 사용될 수 있다.When the cosmetic composition and external skin composition are formulated as a suspension, the carrier ingredients include water, a liquid diluent such as ethanol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester. The same suspending agent, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used.
상기 화장료 조성물 및 피부 외용제 조성물은 비누로 제형화될 때, 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알코올, 식물성 유, 글리세롤, 당 등이 사용될 수 있다.When the cosmetic composition and skin external composition are formulated as soap, the carrier ingredients include alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolysates, isethionates, lanolin derivatives, fatty alcohols, vegetable oil, and glycerol. , sugar, etc. may be used.
상기 화장료 조성물 및 피부 외용제 조성물은 최종 제품의 품질이나 기능에 따라 업계에서 통상적으로 사용되는 지방 물질, 유기용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉 쇄제, 킬레이트화제, 보존제, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 추가적으로 함유할 수 있다.The cosmetic composition and skin external composition may contain fatty substances, organic solvents, solubilizers, thickeners, gelling agents, softeners, antioxidants, suspending agents, stabilizers, and foaming agents commonly used in the industry depending on the quality or function of the final product. agent), fragrance, surfactant, water, ionic or non-ionic emulsifier, filler, metal ion sequestering agent, chelating agent, preservative, blocking agent, wetting agent, essential oil, dye, pigment, hydrophilic or lipophilic activator, cosmetics It may additionally contain auxiliaries commonly used in the fields of cosmetology or dermatology, such as any other commonly used ingredients.
다만, 상기 보조제 및 그 혼합 비율은 본 발명에 따른 화장료 조성물의 바람직한 성질에 영향을 미치지 않도록 적절히 선택할 수 있다.However, the auxiliaries and their mixing ratio may be appropriately selected so as not to affect the desirable properties of the cosmetic composition according to the present invention.
이하 실시예를 통해, 본 발명을 더욱 상술하나 하기 실시예에 의해 본 발명이 제한되지 아니함은 자명하다.The present invention will be described in further detail through the following examples, but it is obvious that the present invention is not limited by the following examples.
제조예 1-1 : 미생물(Preparation Example 1-1: Microorganisms ( Pseudozyma antarcticaPseudozyma antarctica ) 분리 및 동정) Isolation and identification
지리산 얼음골로부터 시료를 채취하여 파쇄하고 균질화시킨 후 이 중 1.0g을 취하여 멸균한 생리식염수(0.9% NaCl) 9.0mL에 현탁하고 단계적으로 희석하여 YM 증식배지에 각각 도말하였다. Samples were collected from Jiri Mountain ice valley, crushed, and homogenized. 1.0 g of the sample was suspended in 9.0 mL of sterilized saline solution (0.9% NaCl), diluted stepwise, and plated on YM growth medium.
25 ℃에서 24 내지 48시간 배양한 다음 집락의 형태가 서로 다른 균주들을 선별하여 여러 번의 순수 배양(pure culture) 과정을 통하여 순수 분리하였다. After culturing at 25°C for 24 to 48 hours, strains with different colony shapes were selected and isolated through several pure culture processes.
순수 분리한 균주를 YM 고체배지에 도말하여 25℃에서 24시간 배양하였으며, 순수 분리된 집락을 YM 액체배지에 배양하여 20%(v/v) 글리세롤(glycerol)l과 1:1의 비율로 혼합하여 -80℃ 초저온 냉동고에 보관하였다.The pure isolated strain was spread on YM solid medium and cultured at 25°C for 24 hours, and the pure isolated colony was cultured on YM liquid medium and mixed with 20% (v/v) glycerol l at a ratio of 1:1. It was stored in an ultra-low temperature freezer at -80°C.
균주를 동정하기 위해 Internal transcribed spacer(ITS) 염기서열과 26S rRNA의 염기서열을 분석한 후, NCBI blast를 검색하여 균주 동정을 하였다. To identify the strain, the internal transcribed spacer (ITS) base sequence and 26S rRNA base sequence were analyzed, and then NCBI blast was searched to identify the strain.
염기서열 분석결과, 분리된 균주는 슈도지마 안타티카(Pseudozyma antarctica)인 것으로 동정되었다. As a result of base sequence analysis, the isolated strain was identified as Pseudozyma antarctica.
상기 동정균을 슈도지마 안타티카 LAB-10 로 명명하였고, 이를 한국생명공학연구원 전북분원 생물자원센터에 2021년 4월 26일자로 기탁하고, 기탁번호 KCTC 14550BP 를 부여받았다.The identified bacterium was named Pseudojima antatica LAB-10, and it was deposited at the Jeonbuk Branch Biological Resources Center of the Korea Research Institute of Bioscience and Biotechnology on April 26, 2021, and was given the deposit number KCTC 14550BP.
제조예 1-2 : 미생물(Preparation Example 1-2: Microorganisms ( Pseudozyma antarcticaPseudozyma antarctica ) 배양액 및 추출액 제조) Culture medium and extract preparation
상기 동정 미생물은 발효를 통해 exopolysaccharide(EPS)를 생성하여 세포 외로 분비하므로, 상기 미생물을 배양하고 이로부터 배양액을 수득하였다. Since the identified microorganism produces exopolysaccharide (EPS) through fermentation and secretes it outside the cell, the microorganism was cultured and a culture medium was obtained therefrom.
상기 동정 미생물의 exopolysaccharide(EPS) 생성 적정배양조건은 배지 내 dextrose 1 내지 1.5 w/v%, yeast extract 0.2 내지 0.4 w/v%, malt extract 0.2 내지 0.4 w/v%, peptone 0.4 내지 0.7 w/v%, 각각의 무기염류 1 내지 1.5 w/v% 로 포함하고, 25℃에서 200rpm으로 36시간 배양 후, 12℃에서 200rpm으로 12시간 배양하였을 때로 확인되었으며, 상기 배양조건에서 미생물로부터 유래되는 EPS 함량은 배양액 내 0.01%로 측정되었다.Appropriate culture conditions for exopolysaccharide (EPS) production of the identified microorganism include 1 to 1.5 w/v% of dextrose in the medium, 0.2 to 0.4 w/v% of yeast extract, 0.2 to 0.4 w/v% of malt extract, and 0.4 to 0.7 w/v of peptone. v%, containing 1 to 1.5 w/v% of each inorganic salt, and was confirmed when cultured at 200 rpm at 25°C for 36 hours and then at 12°C for 12 hours at 200 rpm, and EPS derived from microorganisms under the above culture conditions The content was measured at 0.01% in the culture medium.
배양액의 효능을 분석하기 위해 상기 배지 조성물로 균주를 배양시켜, 생산한 배양액을 5000 x g(10분) 원심 분리하여 상등액만 회수하였다. In order to analyze the efficacy of the culture medium, the strain was cultured with the above medium composition, and the resulting culture liquid was centrifuged at 5000 x g (10 minutes) to recover only the supernatant.
상등액을 0.2 ㎛ 필터를 사용하여 제균 여과 후, 최종 배양액을 수득하였다. The supernatant was filtered for sterilization using a 0.2 ㎛ filter, and the final culture solution was obtained.
추출액의 효능을 분석하기 위해 상기 배지 조성물로 균주를 배양시켜, 생산한 배양액을 초음파추출을 통해 3시간 동안 추출을 진행하고, 5000 x g(10분) 원심 분리하여 상등액만 회수하였다.In order to analyze the efficacy of the extract, the strain was cultured with the above medium composition, and the resulting culture was extracted for 3 hours through ultrasonic extraction, and centrifuged at 5000 x g (10 minutes) to recover only the supernatant.
상등액을 0.2 ㎛ 필터를 사용하여 제균 여과 후, 최종 추출액을 수득하였다.The supernatant was filtered for sterilization using a 0.2 ㎛ filter, and the final extract was obtained.
제조예 2-1 : 미생물(Preparation Example 2-1: Microorganisms ( Pseudoalteromonas neustonicaPseudoalteromonas neustonica )의 분리 및 동정) Isolation and identification of
지리산 얼음골로부터 시료를 채취하여 파쇄하고 균질화시킨 후 이 중 1.0g을 취하여 멸균한 생리식염수(0.9% NaCl) 9.0mL에 현탁하고 단계적으로 희석하여 미생물 증식배지(Difco Nutrient agar)에 각각 도말하였다.Samples were collected from Jiri Mountain ice valley, crushed, and homogenized. 1.0 g of the sample was suspended in 9.0 mL of sterilized saline solution (0.9% NaCl), diluted stepwise, and each plated on microbial growth medium (Difco Nutrient agar).
25℃에서 24 내지 48시간 배양한 다음 집락의 형태가 서로 다른 균주들을 선별하여 여러 번의 순수 배양(pure culture) 과정을 통하여 순수 분리하였다. After culturing at 25°C for 24 to 48 hours, strains with different colony shapes were selected and purified through several pure culture processes.
순수 분리한 균주를 미생물 고체배지에 도말하여 25℃에서 24시간 배양하였으며, 순수 분리된 집락을 NB 액체배지에 배양하여 20%(v/v) 글리세롤(glycerol)l과 1:1의 비율로 혼합하여 -80℃ 초저온 냉동고에 보관하였다.The pure isolated strain was spread on microbial solid medium and cultured at 25°C for 24 hours, and the pure isolated colony was cultured in NB liquid medium and mixed with 20% (v/v) glycerol l at a ratio of 1:1. It was stored in an ultra-low temperature freezer at -80°C.
균주를 동정하기 위해 16S rRNA의 염기서열을 분석한 후, NCBI blast를 검색하여 균주 동정을 하였다.To identify the strain, the 16S rRNA base sequence was analyzed, and then NCBI blast was searched to identify the strain.
염기서열 분석결과, 분리된 균주는 슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica)인 것으로 동정되었다. As a result of base sequence analysis, the isolated strain was identified as Pseudoalteromonas neustonica.
상기 동정균을 슈도알테로모나스 뉴스토니카 LAB-08 로 명명하였고, 이를 한국생명공학연구원 전북분원 생물자원센터에 2021년 4월 26일자로 기탁하고, 기탁번호 KCTC 14549BP 를 부여받았다.The identified bacteria were named Pseudoalteromonas newtonica LAB-08, and it was deposited at the Jeonbuk Branch Biological Resources Center of the Korea Research Institute of Bioscience and Biotechnology on April 26, 2021, and was given the deposit number KCTC 14549BP.
제조예 2-2 : 미생물(Preparation Example 2-2: Microorganisms ( Pseudoalteromonas neustonicaPseudoalteromonas neustonica ) 배양액 및 추출액 제조) Manufacturing of culture medium and extract
상기 동정 미생물은 발효를 통해 세포 내 glyceryl glucoside(GG)를 생성할 수 있으며, 상기 미생물을 배양하고 이로부터 추출된 GG를 포함하는 추출 배양액을 수득하였다. The identified microorganism can produce intracellular glyceryl glucoside (GG) through fermentation, and the microorganism was cultured to obtain an extraction culture containing GG extracted therefrom.
상기 동정 미생물의 glyceryl glucoside(GG) 생성 적정배양조건은 배지 내 tryptone 0.5 내지 1.5 w/v%, yeast extract 0.2 내지 0.4 w/v%, NaCl 0.5 내지 3 w/v%, KCl 0.05 내지 0.1 w/v%, CaCl2 0.1 내지 0.2 w/v%, MgCl2·6H2O 0.3 내지 0.7 w/v%, NaHCO3 0.01 내지 0.02 w/v%, MgSO4·7H2O 0.2 내지 0.4 w/v% 로 포함하며, 25℃에서 200rpm으로 36시간 배양 후, 12℃에서 200rpm으로 12시간 배양하였을 때로 확인되었으며, 상기 배양조건에서 미생물로부터 유래되는 GG 함량은 배양액 내 1.6%로 측정되었다.Appropriate culture conditions for the production of glyceryl glucoside (GG) by the identified microorganism include 0.5 to 1.5 w/v% of tryptone in the medium, 0.2 to 0.4 w/v% of yeast extract, 0.5 to 3 w/v% of NaCl, and 0.05 to 0.1 w/v of KCl. v%, CaCl 2 0.1 to 0.2 w/v%, MgCl 2 ·6H 2 O 0.3 to 0.7 w/v%, NaHCO3 0.01 to 0.02 w/v%, MgSO 4 ·7H 2 O 0.2 to 0.4 w/v% It was confirmed to be cultured at 200 rpm at 25°C for 36 hours and then at 12°C at 200 rpm for 12 hours. Under the above culture conditions, the GG content derived from microorganisms was measured to be 1.6% in the culture medium.
배양액의 효능을 분석하기 위해 상기 배지 조성물로 균주를 배양시켜, 생산한 배양액을 5000 x g(10분) 원심 분리하여 상등액만 회수하였다. In order to analyze the efficacy of the culture medium, the strain was cultured with the above medium composition, and the resulting culture liquid was centrifuged at 5000 x g (10 minutes) to recover only the supernatant.
상등액을 0.2 ㎛ 필터를 사용하여 제균 여과 후, 최종 배양액을 수득하였다. The supernatant was filtered for sterilization using a 0.2 ㎛ filter, and the final culture solution was obtained.
추출액의 효능을 분석하기 위해 상기 배지 조성물로 균주를 배양시켜, 생산한 배양액을 초음파추출을 통해 3시간 동안 추출을 진행하고, 5000 x g(10분) 원심 분리하여 상등액만 회수하였다.In order to analyze the efficacy of the extract, the strain was cultured with the above medium composition, and the resulting culture was extracted for 3 hours through ultrasonic extraction, and centrifuged at 5000 x g (10 minutes) to recover only the supernatant.
상등액을 0.2 ㎛ 필터를 사용하여 제균 여과 후, 최종 추출액을 수득하였다.The supernatant was filtered for sterilization using a 0.2 ㎛ filter, and the final extract was obtained.
실시예 및 비교예Examples and Comparative Examples
본원발명의 균주 배양액 또는 추출액의 피부 개선 효과를 검증하고자 하기와 같이 실시예 및 비교예를 설정하였다.Examples and comparative examples were set as follows to verify the skin improvement effect of the strain culture or extract of the present invention.
본 발명자들이 분리한 Pseudozyma antarctica LAB-10 및 Pseudoalteromonas neustonica LAB-08 균주의 활성을 종래 남극 미생물(Pseudozyma antarctica ATCC34888, Pseudoalteromonas sp. PAMC28425)과 비교하였으며, 2종의 균주 배양액에 의한 시너지 활성을 검증하였다.The activities of the Pseudozyma antarctica LAB-10 and Pseudoalteromonas neustonica LAB-08 strains isolated by the present inventors were compared with conventional Antarctic microorganisms ( Pseudozyma antarctica ATCC34888, Pseudoalteromonas sp. PAMC28425), and the synergistic activity of the two strain cultures was verified.
10% 농도의 배양액을 사용하였으며, 추출액은 1 mg/mL 농도로 하였다.A 10% concentration culture medium was used, and the extract was at a concentration of 1 mg/mL.
LAB-10 배양액 Pseudozyma antarctica
LAB-10 culture medium
실험예 1 : 멜라닌 생성량 평가Experimental Example 1: Evaluation of melanin production amount
멜라민 함량 분석(melanin contents assay)를 통해 실시예 및 비교예의 시료에 의한 멜라닌 형성(melanogenesis) 저해능을 평가하였다.The ability to inhibit melanogenesis by the samples of Examples and Comparative Examples was evaluated through melanin contents assay.
B16F10 cell line을 10% FBS(fetal bovine serum)와 1X 페니실린/스트렙토마이신(P/S)이 함유된 DMEM 배지에 배양하고 세포를 카운팅하였다. The B16F10 cell line was cultured in DMEM medium containing 10% fetal bovine serum (FBS) and 1X penicillin/streptomycin (P/S), and the cells were counted.
24-well 플레이트에 2 x 104 cell/well이 되도록 희석하여 시딩(seeding)하고 5% CO2, 37℃ 배양기에서 24시간 배양하였다. It was diluted to 2 x 10 4 cells/well in a 24-well plate and seeded, and cultured in an incubator at 5% CO 2 and 37°C for 24 hours.
배양 후 10% FBS를 포함하는 배지에 α-msh(α-Melanocyte-stimulating hormone)를 100nM 처리하고 그 배지를 사용하여 시료를 농도별로 희석하여 처리하였다. After culturing, 100 nM α-msh (α-Melanocyte-stimulating hormone) was treated in a medium containing 10% FBS, and the sample was diluted by concentration using the medium.
양성 대조군(positive control)으로는 200ppm arbutin을 사용하였고, 시료와 함께 5% CO2, 37℃ 배양기에서 72시간 배양한 후 배지를 제거하고 DPBS로 cell을 워싱하였다. As a positive control, 200 ppm arbutin was used, and the sample was cultured in an incubator at 5% CO 2 and 37°C for 72 hours, then the medium was removed and the cells were washed with DPBS.
1N NaOH(sodium hydroxide)를 120μL씩 넣고 5% CO2, 37℃ 배양기에서 30분동안 intracellular melanin을 용해시켰다.120 μL of 1N NaOH (sodium hydroxide) was added and intracellular melanin was dissolved in an incubator at 5% CO 2 and 37°C for 30 minutes.
완전히 녹은 intracellular melanin을 100μL씩 96 well 플레이트에 옮기고, 흡광도 측정기기(Multikan Go, Thermo Fisher Scientific)을 이용하여 450nm 에서 흡광도를 측정하였다(도 1, 표 1). 100 μL of completely dissolved intracellular melanin was transferred to a 96 well plate, and the absorbance was measured at 450 nm using an absorbance measuring device (Multikan Go, Thermo Fisher Scientific) (Figure 1, Table 1).
α-msh 를 처리한 군을 control로 하여 결과값을 정리하였다.The results were summarized using the group treated with α-msh as the control.
표 2를 참조하면, 슈도지마 안타티카(Pseudozyma antarctica) 균주 및 슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica) 균주 배양액 또는 추출액을 동시에 포함하는 실시예 1 내지 6은 각각의 단일 균주 배양액 또는 추출액 보다 효과적으로 멜라닌 생성을 억제하였다.Referring to Table 2, Examples 1 to 6, which simultaneously contain Pseudozyma antarctica strain and Pseudoalteromonas neustonica strain culture or extract, produce melanin more effectively than each single strain culture or extract. Production was suppressed.
특히, 각각의 균주 배양액 및 추출액을 동시에 포함하는 실시예 5 및 6의 경우 멜라닌 억제 활성이 더욱 증진되었다.In particular, in the case of Examples 5 and 6, which contained both the culture medium and extract of each strain, the melanin inhibitory activity was further improved.
또한, 단일 균주 간 비교하는 경우라도 본 발명자들이 분리한 Pseudozyma antarctica LAB-10 또는 Pseudoalteromonas neustonica LAB-08 균주 배양액이나 추출액(비교예 1 내지 4)은 종래의 남극 미생물 배양액 또는 추출액(비교예 5 내지 8) 대비 멜라닌 생성 억제능이 우수한 것으로 평가되었다.In addition, even when comparing single strains, the Pseudozyma antarctica LAB-10 or Pseudoalteromonas neustonica LAB-08 strain culture or extract (Comparative Examples 1 to 4) isolated by the present inventors is not the same as the conventional Antarctic microbial culture or extract (Comparative Examples 5 to 8). ) was evaluated as superior in its ability to inhibit melanin production.
상기 결과는 Pseudozyma antarctica LAB-10 및 Pseudoalteromonas neustonica LAB-08 균주의 배양액이나 추출액이 종래 남극 미생물 배양액이나 추출액 대비 더 우수한 피부 개선 활성을 가지며, 동시에 적용될 때 상호 시너지 활성을 나타낼 수 있음을 시사한다.The above results suggest that cultures or extracts of Pseudozyma antarctica LAB-10 and Pseudoalteromonas neustonica LAB-08 strains have better skin improvement activity than conventional Antarctic microbial cultures or extracts, and may exhibit synergistic activity when applied simultaneously.
실험예 2 : 피부 보습 활성 평가Experimental Example 2: Evaluation of skin moisturizing activity
실시예 및 비교예의 시료를 이용하여 피부 보습 효과를 평가하였다.The skin moisturizing effect was evaluated using the samples of Examples and Comparative Examples.
HaCaT cell line을 10% FBS(fetal bovine serum)와 1X 페니실린/스트렙토마이신(P/S)이 함유된DMEM 배지에 배양하고 세포를 카운팅한 뒤 6-well 플레이트에 5 x 105 cell/well이 되도록 희석하여 시딩하고 5% CO2, 37℃ 배양기에서 24시간 배양하였다.HaCaT cell line was cultured in DMEM medium containing 10% FBS (fetal bovine serum) and 1 It was diluted and seeded and cultured in an incubator at 5% CO 2 and 37°C for 24 hours.
배양 후 1% FBS를 포함하는 세럼 프리 배지로 교체 후 기아상태(Starvation)로 만들어 24시간 동안 배양하였다.After culturing, the cells were replaced with serum-free medium containing 1% FBS, starved, and cultured for 24 hours.
시료를 농도 별로 희석하여 처리하고, 양성 대조군(positive control)으로는 10M 레티놀(Retinoic Acid)을 사용하였다.Samples were diluted and processed according to concentration, and 10M Retinol (Retinoic Acid) was used as a positive control.
10M 레티놀을 시료와 함께 5% CO2, 37℃ 배양기에서 24시간 배양한 후 배지를 제거하고 DPBS로 세척하였다. 10M retinol was cultured with the sample in an incubator at 5% CO 2 and 37°C for 24 hours, then the medium was removed and washed with DPBS.
각 시료의 세포에서 RNA Extraction Kit(TaKaRa Mini BEST Universal kit)를 이용해서 RNA를 분리한 뒤 Qubit Fluorometer로 RNA를 정량한 후, 각각 1μg의 RNA를 사용하여 증폭기에서 cDNA를 합성하였다(Step One Plus, Applied Biosystems). RNA was isolated from the cells of each sample using an RNA Extraction Kit (TaKaRa Mini BEST Universal kit), RNA was quantified using a Qubit Fluorometer, and cDNA was synthesized in an amplifier using 1 μg of RNA each (Step One Plus, Applied Biosystems).
Taqman primer AQP3, HAS3, GAPDH는 life technologies사에서 구입해서 사용하였다. Taqman master mix를 사용하여 Real time PCR 장비 Step One Plus Real-Time PCR (Applied Biosystem)를 이용하여 원하는 gene을 증폭하여 유전자 발현량의 변화를 확인하였다(표 3). Taqman primers AQP3, HAS3, and GAPDH were purchased and used from life technologies. Using Taqman master mix, the desired gene was amplified using real-time PCR equipment Step One Plus Real-Time PCR (Applied Biosystem), and changes in gene expression were confirmed (Table 3).
유전자의 발현량은 GAPDH 유전자에 대한 보정을 통해 최종적으로 분석하였다.The expression level of the gene was finally analyzed through correction for the GAPDH gene.
표 3을 참조하면, 슈도지마 안타티카(Pseudozyma antarctica) 균주 및 슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica) 균주 배양액 또는 추출액을 동시에 포함하는 실시예 1 내지 6은 각각의 단일 균주 배양액 또는 추출액 대비 AQP3 및 HAS3 발현을 효과적으로 촉진하였다.Referring to Table 3, Examples 1 to 6, which simultaneously contain Pseudozyma antarctica strain and Pseudoalteromonas neustonica strain culture or extract, have AQP3 and HAS3 expression was effectively promoted.
특히, 각각의 균주 배양액 및 추출액을 동시에 포함하는 실시예 5 및 6의 경우 AQP3 및 HAS3 발현을 더욱 효과적으로 촉진하였다.In particular, in the case of Examples 5 and 6 containing the culture medium and extract of each strain simultaneously, the expression of AQP3 and HAS3 was promoted more effectively.
또한, 단일 균주 간 비교하는 경우라도 본 발명자들이 분리한 Pseudozyma antarctica LAB-10 또는 Pseudoalteromonas neustonica LAB-08 균주 배양액이나 추출액(비교예 1 내지 4)은 종래의 남극 미생물 배양액 또는 추출액(비교예 5 내지 8) 대비 피부 보습 활성이 우수한 것으로 평가되었다.In addition, even when comparing single strains, the Pseudozyma antarctica LAB-10 or Pseudoalteromonas neustonica LAB-08 strain culture or extract (Comparative Examples 1 to 4) isolated by the present inventors is not the same as the conventional Antarctic microbial culture or extract (Comparative Examples 5 to 8). ) was evaluated as having excellent skin moisturizing activity.
상기 결과는 Pseudozyma antarctica LAB-10 및 Pseudoalteromonas neustonica LAB-08 균주의 배양액이나 추출액이 종래 남극 미생물 배양액이나 추출액보다 더 효과적으로 아쿠아포린 단백질의 발현 및 히알루론산의 합성을 촉진시키며, 동시에 적용될 때 상호 시너지 활성을 나타낼 수 있음을 시사한다.The above results show that the culture or extract of the Pseudozyma antarctica LAB-10 and Pseudoalteromonas neustonica LAB-08 strains promotes the expression of aquaporin protein and the synthesis of hyaluronic acid more effectively than the conventional Antarctic microbial culture or extract, and exhibits mutual synergistic activity when applied simultaneously. It suggests that it can be expressed.
실험예 3 : 피부톤 개선 활성 평가Experimental Example 3: Evaluation of skin tone improvement activity
실시예 5의 시료를 로션 타입으로 제형화하고, 피험자 20명을 대상으로 적용한 후 피부의 밝기 변화를 확인하였다.The sample of Example 5 was formulated into a lotion type, applied to 20 subjects, and changes in skin brightness were confirmed.
시험자가 제공하는 기준 세안제를 이용하여 세안 후 페이퍼 타올로 가볍게 두드려 물기를 제거한 후 30 분간 항온, 항습 조건(20 내지 24℃, 40 내지 60% H)에서 안정을 취하게 한 후, MARK Vu(PSI PLUS, Korea)를 사용하여 안면부의 사진촬영을 실시하였다.After washing the face using a standard face wash provided by the tester, lightly pat with a paper towel to remove moisture, allow to stabilize under constant temperature and humidity conditions (20 to 24°C, 40 to 60% H) for 30 minutes, and then mark Vu (PSI). Photographs of the facial area were taken using PLUS, Korea.
평가 시마다 동일한 부위에서 측정이 이루어질 수 있도록 측정 부위를 구획하였으며, 구획된 부위에 실시예 5 및 대조군을 각각 적용하였다.The measurement area was divided so that measurements could be made in the same area for each evaluation, and Example 5 and the control group were applied to the partitioned areas, respectively.
Chromameter(CR-400, Konica-Minolta, Japan)의 측정은 각각 5회씩 시행한 후 측정치의 평균값을 측정값으로 기록하였다.Chromameter (CR-400, Konica-Minolta, Japan) measurements were performed five times each, and the average value of the measurements was recorded as the measurement value.
시험 전, 시험 2주 후, 시험 4주 후에 Chromameter를 이용하여 피부 밝기(L-value)를 측정하고, 피부 밝기 개선율을 산출하였다(표 4, 도 4).Before the test, 2 weeks after the test, and 4 weeks after the test, skin brightness (L-value) was measured using a chromameter, and the skin brightness improvement rate was calculated (Table 4, Figure 4).
표 4를 참조하면, 실시예 5의 시료를 사용한 시험 부위는 시험 2주 후부터 시험 전에 비해 통계적으로 유의한 수준(p<0.05)으로 피부 밝기(L-value)가 증가하였다.Referring to Table 4, the skin brightness (L-value) of the test area using the sample of Example 5 increased to a statistically significant level (p<0.05) from 2 weeks after the test compared to before the test.
또한, 대조군을 사용한 대조 부위와의 비교에서도 통계적으로 유의한 수준(p<0.05)의 차이를 보여 실시예 5의 시료가 피부톤을 효과적으로 개선할 수 있음을 확인하였다.In addition, comparison with the control area using the control group also showed a statistically significant difference (p<0.05), confirming that the sample of Example 5 can effectively improve skin tone.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 예컨대, 단일형으로 설명되어 있는 각 구성 요소는 분산되어 실시될 수도 있으며, 마찬가지로 분산된 것으로 설명되어 있는 구성 요소들도 결합된 형태로 실시될 수 있다.The description of the present invention described above is for illustrative purposes, and those skilled in the art will understand that the present invention can be easily modified into other specific forms without changing the technical idea or essential features of the present invention. will be. Therefore, the embodiments described above should be understood in all respects as illustrative and not restrictive. For example, each component described as single may be implemented in a distributed manner, and similarly, components described as distributed may also be implemented in a combined form.
본 발명의 범위는 후술하는 청구범위에 의하여 나타내어지며, 청구범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.The scope of the present invention is indicated by the claims described below, and all changes or modified forms derived from the meaning and scope of the claims and their equivalent concepts should be construed as being included in the scope of the present invention.
기탁기관명 : 한국생명공학연구원Name of depository institution: Korea Research Institute of Bioscience and Biotechnology
수탁번호 : KCTC14550BPAccession number: KCTC14550BP
수탁일자 : 2021419Trust date: 2021419
기탁기관명 : 한국생명공학연구원Name of depository institution: Korea Research Institute of Bioscience and Biotechnology
수탁번호 : KCTC14549BPAccession number: KCTC14549BP
수탁일자 : 2021419Trust date: 2021419
Claims (8)
슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica) 균주, 이의 발효액, 파쇄액, 추출액 또는 배양액;을 유효성분으로 포함하는 화장료 조성물. Pseudozyma antarctica strain, its fermentation liquid, crushed liquid, extract or culture liquid; and
A cosmetic composition comprising Pseudoalteromonas neustonica strain, its fermentation liquid, crushed liquid, extract or culture liquid as an active ingredient.
상기 슈도지마 안타티카(Pseudozyma antarctica) 균주는 슈도지마 안타티카 LAB-10(수탁번호: KCTC 14550BP) 인, 화장료 조성물.According to paragraph 1,
The Pseudozyma antarctica strain is Pseudozyma antarctica LAB-10 (Accession number: KCTC 14550BP ) Phosphorus, cosmetic composition.
상기 슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica) 균주는 슈도알테로모나스 뉴스토니카 LAB-08(수탁번호: KCTC 14549BP)인, 화장료 조성물.According to paragraph 1,
The cosmetic composition wherein the Pseudoalteromonas neustonica strain is Pseudoalteromonas neustonica LAB-08 (Accession number: KCTC 14549BP).
상기 배양액은 슈도지마 안타티카(Pseudozyma antarctica) 균주 또는 슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica) 균주를 배양하여 수득된 배양액 자체, 또는 이로부터 균주를 제거하여 수득된 배양 상층액, 또는 배양 상층액의 농축물 또는 동결건조물인, 화장료 조성물.According to paragraph 1,
The culture medium is the culture medium itself obtained by culturing the Pseudozyma antarctica strain or the Pseudoalteromonas neustonica strain, or the culture supernatant obtained by removing the strain therefrom, or the culture supernatant. A cosmetic composition, which is a concentrate or lyophilisate.
피부 보습 또는 피부장벽강화용인, 화장료 조성물.According to any one of claims 1 to 4,
A cosmetic composition for moisturizing the skin or strengthening the skin barrier.
피부 미백용 또는 피부톤 개선용인, 화장료 조성물.According to any one of claims 1 to 4,
A cosmetic composition for whitening skin or improving skin tone.
유연화장수, 영양화장수, 수분크림, 영양크림, 마사지크림, 영양로션, 에센스, 앰플, 젤, 아이크림, 오일, 파운데이션, 클렌징크림, 클렌징폼, 클렌징워터, 마스크팩, 스프레이 및 파우더로 이루어진 군에서 선택된 하나의 제형으로 이루어진, 화장료 조성물.According to any one of claims 1 to 4,
A group consisting of softening lotion, nourishing lotion, moisturizing cream, nourishing cream, massage cream, nourishing lotion, essence, ampoule, gel, eye cream, oil, foundation, cleansing cream, cleansing foam, cleansing water, mask pack, spray and powder. A cosmetic composition consisting of one selected formulation.
슈도알테로모나스 뉴스토니카(Pseudoalteromonas neustonica) 균주, 이의 발효액, 파쇄액, 추출액 또는 배양액;을 유효성분으로 포함하는 피부외용제 조성물.
Pseudozyma antarctica strain, its fermentation liquid, crushed liquid, extract or culture liquid; and
Pseudoalteromonas neustonica ( Pseudoalteromonas neustonica ) strain, its fermentation liquid, crushed liquid, extract or culture medium; a skin external composition comprising as an active ingredient.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210084867A KR102652692B1 (en) | 2021-06-29 | 2021-06-29 | A cosmetic compositon comprising antarctic microorganism |
| PCT/KR2022/007832 WO2023277367A1 (en) | 2021-06-29 | 2022-06-02 | Cosmetic composition comprising antarctic microorganism culture medium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210084867A KR102652692B1 (en) | 2021-06-29 | 2021-06-29 | A cosmetic compositon comprising antarctic microorganism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230003710A KR20230003710A (en) | 2023-01-06 |
| KR102652692B1 true KR102652692B1 (en) | 2024-04-01 |
Family
ID=84692834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210084867A KR102652692B1 (en) | 2021-06-29 | 2021-06-29 | A cosmetic compositon comprising antarctic microorganism |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102652692B1 (en) |
| WO (1) | WO2023277367A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009034090A (en) | 2007-07-09 | 2009-02-19 | Toyobo Co Ltd | Mannosyl erythritol lipid and method for producing the same |
| JP2009126820A (en) | 2007-11-22 | 2009-06-11 | Toyobo Co Ltd | New mannosyl erythritol lipid and method for producing the same |
| US20110195103A1 (en) | 2008-10-13 | 2011-08-11 | Lipotec, S.A. | Cosmetic or dermopharmaceutical composition containing pseudoalteromonas ferment extract |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2814552T3 (en) * | 2014-10-31 | 2021-03-29 | Lipotec S A U | Cosmetic and / or pharmaceutical composition containing a bacterial extracellular product of Pseudoalteromonas antarctica and its use |
| KR20180028131A (en) * | 2016-09-08 | 2018-03-16 | (주)아모레퍼시픽 | Composition for skin whitening comprising mannosylerythritol lipid |
-
2021
- 2021-06-29 KR KR1020210084867A patent/KR102652692B1/en active IP Right Grant
-
2022
- 2022-06-02 WO PCT/KR2022/007832 patent/WO2023277367A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009034090A (en) | 2007-07-09 | 2009-02-19 | Toyobo Co Ltd | Mannosyl erythritol lipid and method for producing the same |
| JP2009126820A (en) | 2007-11-22 | 2009-06-11 | Toyobo Co Ltd | New mannosyl erythritol lipid and method for producing the same |
| US20110195103A1 (en) | 2008-10-13 | 2011-08-11 | Lipotec, S.A. | Cosmetic or dermopharmaceutical composition containing pseudoalteromonas ferment extract |
Non-Patent Citations (1)
| Title |
|---|
| LABIO, 뉴스레터, "Antarctic-G: 지구의 시작, 남극에서 온 수분, 톤업 밸런싱"(2021.06.28.) 1부.* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230003710A (en) | 2023-01-06 |
| WO2023277367A1 (en) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2110123B1 (en) | Fibroblast proliferator | |
| KR102156898B1 (en) | Ingestible cosmetic composition for skin whitening, skin moisturizing, antioxidant, anti-inflammatory, skin barrier strengthening and skin absorption containing the lactic acid fermentation mixture | |
| KR101663946B1 (en) | Cosmetic composition containing an ginsenoside Rg3 reinforced extract of fermentative Ginseng flower(Panax ginseng C. A. Meyer) by Aureobasidium pullulans | |
| JP7210814B2 (en) | METHOD FOR CULTIVATING GALLERY | |
| US20230414683A1 (en) | Antioxidant, anti-inflammatory, and whitening composition comprising skin-derived lactic acid bacteria | |
| US20220211610A1 (en) | Skin whitening cosmetic composition comprising lactobacillus rhamnosus lm1011 having immunostimulating activity | |
| KR101855207B1 (en) | Cosmetic composition containing fermentative extract of terminalia ferdinandiana with increased amount of vitamin c fermented by aureobasidium pullulans | |
| KR101645476B1 (en) | Cosmetic Composition containing Fermentative Extract of Hippophae rhamnoides with Increased Amount of Vitamin C Fermented by Aureobasidium pullulans | |
| JP6754166B2 (en) | Cosmetics | |
| KR102373899B1 (en) | Multifunctional cosmetic composition containing complex natural extracts effective for skin wrinkle improvement, whitening, cell regeneration, and wound healing as an active ingredient | |
| KR102652692B1 (en) | A cosmetic compositon comprising antarctic microorganism | |
| FR2997853A1 (en) | Reducing or delaying the thinning of skin and the sagging of skin and stimulating cellular metabolism of keratinocytes, comprises applying effective quantity of an extract of Myrothamnus flabellifolia to skin | |
| KR102395984B1 (en) | Composition for whitening of skin comprising culture or its extract of pseudoalteromonas carrageenovora | |
| KR101843976B1 (en) | Cosmetic composition comprising extract of geminated phaseolus radiatus fermented by aureobasidium pullulans | |
| JP2015134737A (en) | External preparation for skin | |
| KR102390656B1 (en) | A cosmetic composition comprising chlorella extract for skin-whitening | |
| KR101997231B1 (en) | Cosmetic composition containing enzyme-treated honey extract | |
| JP6375087B2 (en) | Cosmetics | |
| KR102107193B1 (en) | Cosmetic composition comprising extract of calendula arvensis fermented by aureobasidium pullulans | |
| KR101987425B1 (en) | A cosmetic composition comprising salix gracilistyla extract | |
| KR102018512B1 (en) | Cosmetic composition comprising extract of saliva miltiorrhiza fermented by aureobasidium pullulans | |
| KR101971257B1 (en) | A cosmetic composition comprising tenebrio molitor extract | |
| CN112438898A (en) | Cosmetic composition for moisturizing skin and improving skin barrier comprising electrolyte material | |
| KR101521239B1 (en) | Cosmetic composition for anti-aging containing the extract of fermentative Scutellaria baicalensis by Laetiporus Sulphureus | |
| KR102643628B1 (en) | A composition for improving milium comprising lactic acid bacteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |